Novel oral anticoagulant use in adults with congenital heart disease: a single-center experience report

BACKGROUND: Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants...

Descripción completa

Detalles Bibliográficos
Autores principales: Samarai, Daniel, Isma, Nazim, Lindstedt, Sandra, Hlebowicz, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829939/
https://www.ncbi.nlm.nih.gov/pubmed/36624331
http://dx.doi.org/10.1186/s43044-022-00326-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829939/
https://www.ncbi.nlm.nih.gov/pubmed/36624331
http://dx.doi.org/10.1186/s43044-022-00326-1

Ejemplares similares